BriaCell Therapeutics Corp. announced it has identified a new group of patients with high levels of clinical benefit in response to its novel immunotherapy, and its combinations. Breast cancer is subdivided into 3 categories based on its appearance under the microscope: Grade 1 (well differentiated), Grade II (moderately differentiated) and Grade III (poorly differentiated). The Bria-IMT™ cell line was derived from a Grade II tumor biopsy. Upon reanalysis of clinical data, it learned of correlative patterns of tumor response in Grade I/II breast cancer patient populations. In view, this seems logical because Bria-IMT™ is derived from a Grade II (moderately differentiated) breast cancer tumor. Importantly, approximately 40% of recurrent breast cancers are Grade I/II.